Gainers

• Milestone Scientific (AMEX:MLSS) stock moved upwards by 11.8% to $0.44 during Monday's after-market session. The company's market cap stands at $36.9 million.
• Evotec (NASDAQ:EVO) stock rose 8.44% to $1.67. The company's market cap stands at $568.6 million.
• Universe Pharmaceuticals (NASDAQ:UPC) stock rose 6.46% to $4.94. The market value of their outstanding shares is at $24.4 million.
• NovaBridge Biosciences (NASDAQ:NBP) shares increased by 6.21% to $1.71. The company's market cap stands at $184.4 million.
• AnaptysBio (NASDAQ:ANAB) shares increased by 5.62% to $58.01. The market value of their outstanding shares is at $1.6 billion. As per the press release, Q2 earnings came out today.
• Creative Medical Tech (NASDAQ:CELZ) shares moved upwards by 5.47% to $1.06. The market value of their outstanding shares is at $6.3 million.

Losers

• CytoMed Therapeutics (NASDAQ:GDTC) shares declined by 15.4% to $0.82 during Monday's after-market session. The company's market cap stands at $11.5 million.
• Beyond Air (NASDAQ:XAIR) stock decreased by 7.35% to $2.9. The market value of their outstanding shares is at $3.0 million.
• Quest Diagnostics (NYSE:DGX) shares decreased by 6.9% to $228.0. The market value of their outstanding shares is at $27.2 billion.
• Mira Pharmaceuticals (NASDAQ:MIRA) shares declined by 6.69% to $0.82. The company's market cap stands at $34.9 million.
• Silexion Therapeutics (NASDAQ:SLXN) stock declined by 6.07% to $0.51. The company's market cap stands at $2.4 million.
• iTonic Holdings (NASDAQ:ITOC) stock fell 6.07% to $0.31. The company's market cap stands at $5.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.